Mike Schultz had spent more than a decade in his lab at the University of Iowa discovering a pair of radioactive substances that could detect and destroy cancer cells. Fran Johnson, his wife, had spent just as much time running the university medical center’s heart disease treatment program. So, when they launched a startup in 2015, the division of work was obvious. Mike stayed at the university to continue his research, and Fran left to run the company. Viewpoint Molecular Targeting in 2023 merged with Isoray to form a new public company called Perspective Therapeutics.  It’s headquartered in Seattle and has about one third of its employees in Iowa.

Midwest Moxie's executive producer is Audrey Nowakowski. She produced this episode. Subscribe to Midwest Moxie wherever you get your podcasts. And if you love Midwest Moxie as much as we do, help us out by posting a review.